Shanghai Rendu Biotechnology Co. Ltd. A (688193) - Net Assets
Based on the latest financial reports, Shanghai Rendu Biotechnology Co. Ltd. A (688193) has net assets worth CN¥918.58 Million CNY (≈ $134.42 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥984.02 Million ≈ $143.99 Million USD) and total liabilities (CN¥65.45 Million ≈ $9.58 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See 688193 net asset quality score to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥918.58 Million |
| % of Total Assets | 93.35% |
| Annual Growth Rate | 35.04% |
| 5-Year Change | 217.61% |
| 10-Year Change | N/A |
| Growth Volatility | 83.89 |
Shanghai Rendu Biotechnology Co. Ltd. A - Net Assets Trend (2019–2025)
This chart illustrates how Shanghai Rendu Biotechnology Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Shanghai Rendu Biotechnology Co. Ltd. A (688193) total market value.
Annual Net Assets for Shanghai Rendu Biotechnology Co. Ltd. A (2019–2025)
The table below shows the annual net assets of Shanghai Rendu Biotechnology Co. Ltd. A from 2019 to 2025. Also explore Shanghai Rendu Biotechnology Co. Ltd. A annual equity growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥913.91 Million ≈ $133.73 Million |
+0.22% |
| 2024-12-31 | CN¥911.88 Million ≈ $133.44 Million |
-5.28% |
| 2023-12-31 | CN¥962.74 Million ≈ $140.88 Million |
+0.14% |
| 2022-12-31 | CN¥961.38 Million ≈ $140.68 Million |
+234.11% |
| 2021-12-31 | CN¥287.75 Million ≈ $42.11 Million |
+33.82% |
| 2020-12-31 | CN¥215.03 Million ≈ $31.47 Million |
+42.73% |
| 2019-12-31 | CN¥150.66 Million ≈ $22.05 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Rendu Biotechnology Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 23938728945.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥114.37 Million | 12.51% |
| Other Components | CN¥799.54 Million | 87.49% |
| Total Equity | CN¥913.91 Million | 100.00% |
Shanghai Rendu Biotechnology Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Shanghai Rendu Biotechnology Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Corby Spirit and Wine Limited
TO:CSW-A
|
$267.08 Million |
|
RichWave Technology Corp
TW:4968
|
$267.27 Million |
|
Provident Agro Tbk
JK:PALM
|
$267.35 Million |
|
Alpine Income Property Trust, Inc.
NYSE:PINE
|
$267.42 Million |
|
Peach Property Group AG
SW:PEAN
|
$267.03 Million |
|
RF Acquisition Corp II Ordinary Shares
NASDAQ:RFAI
|
$267.00 Million |
|
Soechi Lines Tbk
JK:SOCI
|
$266.79 Million |
|
Singer Thailand Public Company Limited
BK:SINGER
|
$266.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Rendu Biotechnology Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 911,879,373 to 913,909,494, a change of 2,030,121 (0.2%).
- Net income of 10,087,386 contributed positively to equity growth.
- Dividend payments of 9,687,624 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥10.09 Million | +1.1% |
| Dividends Paid | CN¥9.69 Million | -1.06% |
| Other Changes | CN¥1.63 Million | +0.18% |
| Total Change | CN¥- | 0.22% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Rendu Biotechnology Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.00x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 9.07x to 2.00x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥5.02 | CN¥45.55 | x |
| 2020-12-31 | CN¥7.17 | CN¥45.55 | x |
| 2021-12-31 | CN¥9.59 | CN¥45.55 | x |
| 2022-12-31 | CN¥24.03 | CN¥45.55 | x |
| 2023-12-31 | CN¥24.07 | CN¥45.55 | x |
| 2024-12-31 | CN¥22.80 | CN¥45.55 | x |
| 2025-12-31 | CN¥22.81 | CN¥45.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Rendu Biotechnology Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.23%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.08x
- Recent ROE (1.10%) is below the historical average (8.14%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 2.48% | 3.77% | 0.53x | 1.24x | CN¥-11.33 Million |
| 2020 | 28.54% | 24.56% | 0.80x | 1.45x | CN¥39.87 Million |
| 2021 | 22.46% | 22.11% | 0.77x | 1.32x | CN¥35.84 Million |
| 2022 | 2.43% | 7.68% | 0.28x | 1.13x | CN¥-72.81 Million |
| 2023 | 0.86% | 5.02% | 0.16x | 1.10x | CN¥-88.01 Million |
| 2024 | -0.86% | -4.40% | 0.18x | 1.09x | CN¥-99.00 Million |
| 2025 | 1.10% | 6.23% | 0.16x | 1.08x | CN¥-81.30 Million |
Industry Comparison
This section compares Shanghai Rendu Biotechnology Co. Ltd. A's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $1,956,613,681
- Average return on equity (ROE) among peers: 13.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Rendu Biotechnology Co. Ltd. A (688193) | CN¥918.58 Million | 2.48% | 0.07x | $267.08 Million |
| Berry Genomics Co Ltd (000710) | $220.90 Million | 6.22% | 0.35x | $468.17 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $1.06 Billion | 16.51% | 1.16x | $1.74 Billion |
| Hangzhou Tigermed Consulting (300347) | $916.90 Million | 13.69% | 0.48x | $6.20 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $1.70 Billion | 17.66% | 0.10x | $978.07 Million |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $2.29 Billion | 10.04% | 0.87x | $533.70 Million |
| Maccura Biotechnology Co Ltd (300463) | $2.28 Billion | 13.67% | 0.18x | $803.41 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $5.23 Billion | 33.02% | 0.29x | $558.16 Million |
| BGI Genomics Co Ltd (300676) | $4.46 Billion | 6.20% | 0.34x | $2.43 Billion |
| Amoy Diagnostics Co Ltd (300685) | $307.91 Million | 21.77% | 0.15x | $1.04 Billion |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $1.10 Billion | 0.58% | 0.20x | $644.10 Million |
About Shanghai Rendu Biotechnology Co. Ltd. A
Shanghai Rendu Biotechnology Co., Ltd. engages in the research, development, production, and sales of RNA molecular diagnostic technology and products. It offers products in the areas of reproductive health, bloodborne infections, respiratory infections, enterovirus infections, cancer early detection, and other areas; and AutoSAT, SuperSAT, and ultrasonic homogenizer. The company was founded in 2… Read more